[go: up one dir, main page]

CA2207025A1 - Utilisation d'additifs ajoutes a des agents contrastants pour ameliorer l'imagerie - Google Patents

Utilisation d'additifs ajoutes a des agents contrastants pour ameliorer l'imagerie

Info

Publication number
CA2207025A1
CA2207025A1 CA 2207025 CA2207025A CA2207025A1 CA 2207025 A1 CA2207025 A1 CA 2207025A1 CA 2207025 CA2207025 CA 2207025 CA 2207025 A CA2207025 A CA 2207025A CA 2207025 A1 CA2207025 A1 CA 2207025A1
Authority
CA
Canada
Prior art keywords
inn
stands
nuclear
ultrasonic
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2207025
Other languages
English (en)
Inventor
Werner Krause
Ulrich Speck
Wolf-Rudiger Press
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2207025A1 publication Critical patent/CA2207025A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/46—Unsaturated compounds containing hydroxy or O-metal groups containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/62—Unsaturated compounds containing ether groups, groups, groups, or groups containing rings other than six-membered aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne l'utilisation de dérivés de prostacycline, ainsi que celle d'urée pour améliorer l'imagerie dans les diagnostics effectués par radiographie, ultrasons, résonance magnétique ou résonance magnétique nucléaire.
CA 2207025 1994-12-09 1995-12-08 Utilisation d'additifs ajoutes a des agents contrastants pour ameliorer l'imagerie Abandoned CA2207025A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19944446694 DE4446694A1 (de) 1994-12-09 1994-12-09 Verwendung von Zusätzen zu Kontrastmitteln zur Verbesserung der Bildgebung
DEP4446694.3 1994-12-09

Publications (1)

Publication Number Publication Date
CA2207025A1 true CA2207025A1 (fr) 1996-06-13

Family

ID=6537194

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2207025 Abandoned CA2207025A1 (fr) 1994-12-09 1995-12-08 Utilisation d'additifs ajoutes a des agents contrastants pour ameliorer l'imagerie

Country Status (6)

Country Link
EP (1) EP0789594A1 (fr)
JP (1) JPH10509691A (fr)
CA (1) CA2207025A1 (fr)
DE (1) DE4446694A1 (fr)
NO (1) NO972613L (fr)
WO (1) WO1996017629A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257305B2 (en) 2002-09-20 2012-09-04 Bayer Pharma Aktiengesellschaft Medical device for dispensing medicaments
US8389043B2 (en) 2001-03-26 2013-03-05 Bayer Pharma Aktiengesellschaft Preparation for restenosis prevention

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE251893T1 (de) * 1996-01-25 2003-11-15 Schering Ag Verbesserte kontrastmittenlösungen für die intravasale anwendung
EP1106177A4 (fr) * 1999-06-14 2002-03-13 Toray Industries Composes facilitant l'accumulation de medicaments dans des tissus tumoraux
EP2324867B1 (fr) 2002-07-12 2014-06-18 Cook Medical Technologies LLC Ballons d'angioplastie revêtis d'agents pharmaceutiques en forme expansée

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450149A (en) * 1981-06-15 1984-05-22 Research Corporation Radiohalogenation method
JPH0669966B2 (ja) * 1989-07-05 1994-09-07 株式会社ミドリ十字 血管造影補助剤
US5334369A (en) * 1991-06-11 1994-08-02 Medical University Of South Carolina Platelet receptor antagonists useful in detecting intravascular platelet aggregation
DE4135193C1 (fr) * 1991-10-22 1993-03-11 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8389043B2 (en) 2001-03-26 2013-03-05 Bayer Pharma Aktiengesellschaft Preparation for restenosis prevention
US9066990B2 (en) 2001-03-26 2015-06-30 Bayer Intellectual Property Gmbh Preparation for restenosis prevention
US8257305B2 (en) 2002-09-20 2012-09-04 Bayer Pharma Aktiengesellschaft Medical device for dispensing medicaments
US8439868B2 (en) 2002-09-20 2013-05-14 Bayer Pharma AG Medical device for dispersing medicaments
US9649476B2 (en) 2002-09-20 2017-05-16 Bayer Intellectual Property Gmbh Medical device for dispersing medicaments

Also Published As

Publication number Publication date
JPH10509691A (ja) 1998-09-22
EP0789594A1 (fr) 1997-08-20
WO1996017629A1 (fr) 1996-06-13
DE4446694A1 (de) 1996-06-13
NO972613D0 (no) 1997-06-06
NO972613L (no) 1997-06-06

Similar Documents

Publication Publication Date Title
US4886788A (en) Cyclodextrin clathrates of carbacyclin derivatives and their use as medicinal agents
CA1264320A (fr) Analogues des prostaglandines, procede de preparation et composes pharmaceutiques les contenant
JPH0640919A (ja) 高眼圧症あるいは緑内障の治療剤
JP2597649B2 (ja) 気管・気管支拡張剤
JPH0611726B2 (ja) （５Ｅ）−１３，１４，１８，１８，１９，１９−ヘキサデヒドロ−３−オキサ−６ａ−カルバプロスタグランジン−Ｉ▲下２▼−誘導体、その製法並びに該化合物を含有する血圧降下剤
CA2207025A1 (fr) Utilisation d'additifs ajoutes a des agents contrastants pour ameliorer l'imagerie
US5814301A (en) Use of prostacyclin derivatives to prevent or to treat disorders of the microcirculatory system when x-ray, NMR or ultrasonic contrast media are administered
US5397797A (en) Treatment of ocular hypertension with an ocular synergistic combination
US5010065A (en) Cyclodextrin clathrates of 5-cyanoprostacyclin derivatives and their use as pharmaceutical agents
US5254588A (en) Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds
CA2030344C (fr) Traitement de troubles pulmonaires a l'aide de composes de 15-ceto-prostaglandines
JP2511611B2 (ja) 眼圧降下用医薬組成物
EP0430551A2 (fr) Traitement de la dysfonction cardiaque à l'aide de dérivés 15-céto-prostaglandine
JP3183615B2 (ja) 肝・胆道系疾患処置剤
US5162370A (en) Treatment of cataract with prostacyclin compounds
US6040336A (en) Prostane derivatives and the combination thereof with antibiotics in the treatment of bacterial infections
USRE34756E (en) Excretion of potassium ion by prostanoic acid derivatives
JPH0355461B2 (fr)
JP2760514B2 (ja) 循環機能昂進剤
JP2820504B2 (ja) イソカルバサイクリン誘導体
JPH0791192B2 (ja) ガス交換機能不全処置剤
JPH0564932B2 (fr)
JPH0296529A (ja) 眼圧降下剤
JPH089544B2 (ja) 腸内排泄剤
JPWO2001066518A1 (ja) ω−置換フェニル−プロスタグランジンＥ−アルコール、それらの製造方法およびそれらを有効成分として含有する薬剤

Legal Events

Date Code Title Description
FZDE Dead